Sensorion Announces Attendance at the 41st Annual JP Morgan Healthcare Meeting in San Francisco
Montpellier, December 5, 2022 – Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company dedicated to the development of innovative therapies to restore, treat and prevent hearing loss, announces that its management team, including Nawal Ouzren, Chief Executive Officer , will attend the 41st Annual JP Morgan Meeting, to be held in San Francisco, USA, from January 9-12, 2023.